Maintaining Investments in New Innovation Act

1/2
Status In Committee
Sponsor Wiley Nickel
Citation 118-HR-5547
Actions 5
Introduced Sep 18th, 2023
Cosponsors
23 5
Last Action Dec 17th, 2024
Policy Area
Introduced House Sep 18
House
Senate
President
Enacted

Summary

AI Guide

What this bill does

Loading AI analysis…

Maintaining Investments in New Innovation Act This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

Actions

5
House
INTRODUCED
INTRODUCED
Sep 18, 2023
ON FLOOR
REFERRED TO COMMITTEE
ON FLOOR
REFERRED TO COMMITTEE
COMMITTEE
REFERRED TO SUBCOMMITTEE
Sep 22, 2023
COMMITTEE
REFERRED TO SUBCOMMITTEE
Dec 17, 2024
Version
Font size